Roche and Merck Serono recently sized up their chances to pass muster with the UK's cost-effectiveness regulators and decided to give NICE a pass. Analysts say that the clinical- and cost-effectiveness evaluators at NICE have been turning an increasingly skeptical eye on some of the expensive biologics coming their way. And that helped persuade both big pharma companies to forget about making full submissions to NICE on Avastin and Erbitux. Article